在瘤群体中评估甲和QTc间隔延长的风险
Daniel Yuwen Li1, Serena Kim2, Saba Javed3
1University of Texas McGovern Medical School, Houston, Texas, USA Daniel.Li@uth.tmc.edu.
Regional anesthesia and pain medicine
|February 17, 2026
概括
在癌症疼痛管理中使用甲,在12个月后显示出小,统计学上显著的QTc间隔增加. 心脏病并发症更显著地增加了QTc,但大多数患者没有出现不良反应.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 甲是用于治疗癌症疼痛的常见阿片类药物.
- 高剂量的甲与QTc延长有关;较低的癌症疼痛剂量的影响较少.
研究的目的:
- 为了评估心血管效应,特别是QTc间隔变化,在癌症患者使用美沙来治疗疼痛.
主要方法:
- 对492名接受甲治疗的成人癌症患者的回顾性图表审查.
- 收集了基线和随访时ECG的人口统计,临床数据和QTc间隔.
主要成果:
- 在开始服用美沙后≥12个月后,观察到4.36毫秒的统计学意义上的QTc增加.
- 心脏病并发症与9.40毫秒的QTc增加有关.
- 在12个月后,整体QTc延长率从3%上升到6.8%.
结论:
- 甲与癌症患者≥12个月后的小,统计学上显著的QTc增加有关.
- 这种QTc变化不太可能导致大多数患者的临床问题.
- 建议在癌症疼痛中使用甲的风险分层方法,对高风险个体进行有针对性的心电图监测.
相关概念视频
Drug Toxicity: Risk factors
27
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
27
Therapeutic Drug Monitoring: Affecting Factors
258
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
258
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
24
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
24
Therapeutic Drug Monitoring: Overview and Classification
388
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
388
Drug Dosing: Geriatric Patients
289
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
289
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
18
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
18


